Uluru, a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products, has received CE mark certification in all countries within the European Economic Area (EEA) for its Altrazeal Transforming Powder Dressing.
Following the CE mark, Uluru is investigating potential collaborations to launch Altrazeal in the first European market. Assuming the successful completion of a collaboration, Altrazeal could potentially be launched in Europe prior to year end.
Kerry Gray, president and CEO of Uluru, said: “The issuance of a CE mark for Altrazeal represents a significant milestone for the commercial expansion of our advanced woundcare product. This prestigious CE mark designation for Altrazeal provides the company with significant licensing and marketing opportunities throughout the EEA.
“In addition, the standards required to be met for granting a CE mark are expected to also allow Uluru to more quickly gain approval for marketing this innovative product in Asia, South America, and other territories. CE marking is mandatory for advanced wound dressings and is the necessary approval for marketing in the EEA which consists of 27 Member States of the EU and EFTA countries.”